Project Grant R01AR087006
- Federal Project Grant Award Summary This five-year training and research grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports $258,070 in total obligated funding (awarded September 26, 2025, with completion by August 31, 2030) to Washington University. The award funds a mentored research program designed to develop a physician-scientist's expertise in...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $581,451 (awarded June 1, 2026; completion date March 31, 2031) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research aims to elucidate the neuroimmune mechanisms underlying pruritus (itch), specifically investigating how microbiota-induced cytokines and immune...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded $1.9M in Project Grant funding (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, San Francisco on September 15, 2025, for a three-year research initiative through August 31, 2028. This award supports research into the dysregulation of epidermal innate immune signaling as a driver of psoriatic arthritis (PsA). The project...
- Federal Project Grant Award Summary New York University School of Medicine received a $148,062 Project Grant award effective September 30, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds basic research investigating the mechanisms of inflammatory memory in human epithelial cells, with completion targeted for May 31, 2028. The funded research will...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $528,558 (awarded September 1, 2025, with completion by August 31, 2030) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research project investigates T-cell plasticity mechanisms underlying treatment resistance and paradoxical inflammatory side effects in atopic...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $3.65 million Project Grant to the University of Miami's Office of Research Administration – School of Medicine, effective September 1, 2025, through August 31, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This grant funds a comprehensive research initiative titled "Unraveling the Role of Langerhans Cells in Itch" that...
- Federal Project Grant Award Summary The University of Pennsylvania received a $2.06 million Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded June 1, 2026, with completion targeted for May 31, 2030. This award funds basic and translational research to elucidate the role of protein translation efficiency in T cell adaptation to human skin tissue. The...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Leland Stanford Junior University a Project Grant of $204,682 on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to support research on RNA-dependent protein assemblies in epidermal homeostasis through June 30, 2027. The funded research addresses the mechanistic gap in understanding how RNA-binding proteins...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant totaling $224,100 to the Regents of the University of California at Riverside under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award, effective September 15, 2025, through August 31, 2028, funds research to identify epigenetic factors controlling epidermal stem cell longevity in adult skin. The project addresses the...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $524,335 Project Grant award dated June 5, 2026, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports basic research investigating the dynamic regulation of epidermal differentiation genes through cell-state-specific protein interactions of the PBAF chromatin...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $483,286 Project Grant to Washington University (awarded July 6, 2026; completion June 30, 2031) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research grant funds a comprehensive scientific investigation into the role of CD5+ dendritic cells in driving autoimmune skin inflammation, with particular application to psoriasis and immune-related adverse effects. The project will deliver research products through three coordinated aims: (1) defining molecular pathways governing CD5+ dendritic cell differentiation using transcriptomics and in vivo models; (2) investigating antigen handling and presentation mechanisms driving autoreactive T cell responses; and (3) identifying immune pathway regulators through spatial proteomics and transcriptomics analysis comparing treatment responders and non-responders to map cellular interactions. These research activities are designed to advance understanding of immune tolerance mechanisms in skin and generate therapeutic strategies to restore immune balance in chronic inflammatory conditions affecting approximately 125 million people worldwide. The work will be conducted at Washington University's St. Louis, Missouri facility and will produce peer-reviewed scientific publications, experimental datasets, and translational findings to inform development of new therapeutic interventions for psoriasis, graft-versus-host disease, and immune-related adverse effects associated with cancer immunotherapies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $483.3k | 7/7/26 |